Please ensure Javascript is enabled for purposes of website accessibility

Why Sorrento Therapeutics Stock Flew Nearly 7% Higher on Monday

By Eric Volkman – Jun 14, 2021 at 6:03PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company got the green light to launch phase 2 testing in the U.K. for its experimental COVID-19 treatment.

What happened

Sorrento Therapeutics (SRNE -8.88%) didn't have a case of the Mondays at all. The company's stock zoomed 6.7% higher today on very encouraging news from across the pond.

So what

After U.S. market hours on Friday, Sorrento divulged that the U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA) has authorized the company to begin a phase 2 efficacy trial of its COVIDROPS, an experimental stem-cell drug to combat COVID-19. The regulator's decision is based on safety data from an earlier study conducted in the U.S. by the California-based biotech.

A scientist working on a lab sample.

Image source: Getty Images.

The trial will be a double-blind clinical study involving 350 participants afflicted with COVID who are asymptomatic or mildly symptomatic. They will receive a 10-milligram or 20-milligram dose, or a placebo. This research will accompany both a phase 2 trial in the U.S., and a separate study in Mexico.

Sorrento said that if COVIDROPS prove efficacious and safe to administer in the three trials, the company will apply for Emergency Use Authorization from the Food and Drug Administration. It will also seek similar authorization in the U.K., the European Union, India, and Mexico, among other jurisdictions.

Now what

While much of the world is covered by coronavirus vaccines, there is still a need for an authorized drug to treat instances of infection. Sorrento's COVIDROPS getting the green light for important clinical testing is indisputably good news for the company...and, hopefully, for a planet with regions still in the grip of the pandemic.

 

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sorrento Therapeutics, Inc. Stock Quote
Sorrento Therapeutics, Inc.
SRNE
$1.54 (-8.88%) $0.15

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
342%
 
S&P 500 Returns
107%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.